TrialWorld journal of gastrointestinal oncology2024

Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers.

Zhe-Han Bao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.